Generic Name: obeticholic acid
Drug Class: NAFLD/NASH Medications
Company: Intercept Pharmaceuticals
Approval Status: Experimental
Generic Version Available: No
Experimental Code: OCA
Ocaliva is a semi-synthetic bile acid analog that has been shown to help reduce markers of liver inflammation and fibrosis, as well as increase insulin sensitivity in liver disease patients. Ocaliva is in Phase 3 clinical trials as a possible treatment for NASH. Ocaliva is already FDA-approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Dosing Info: N/A
For information about Ocaliva’s use for PBC, visit ocaliva.com.
Last Reviewed: February 4, 2019